Teva Barred From Agreeing ‘No-Authorized Generics’ Deals Under Reverse-Payment FTC Settlement

 
• By Dean Rudge

Modifying terms to a 2015 consent decree involving its Cephalon unit, Teva has reached a global settlement agreement with the US Federal Trade Commission that dismisses Teva and its affiliates from three outstanding antitrust cases.

FTC
Teva Has Struck A Deal With The FTC To Resolve Pending Claims In Three Cases • Source: Shutterstock

More from Strategy

More from Business